News

In some kids, an RSV infection is mild, while others are hospitalized. Natural killer cells might be the reason why.

Novartis’ iscalimab may improve troubling symptoms in patients with Sjögren’s disease, though there may be safety concerns to address.

Injectable micelles that release glucagon could provide a new way to treat hypoglycemic events in diabetes.

The link between metabolism and sleep is helping scientists find new biomarkers to detect sleepless nights and diagnose chronic sleep disorders.

Structural analysis of the herpes simplex virus polymerase revealed that mutations affecting its drug binding and flexibility may drive treatment resistance.

Gut microbes can protect or sensitize each other to drugs, even to non-antibiotics.

With new tools, researchers hope to improve diagnosis of platelet dysfunction by measuring their forces.

After tackling toxicity and a trial halt, Elena Koundourakis and her team at Takeda are on the cusp of a first-in-class drug for people living with narcolepsy.

Rett syndrome currently has no cure. Now, innovations in gene therapy bring the possibility of treating the root cause of the disease closer than ever before.

A liver enzyme affects fibrosis progression by altering metabolism of the sugar trehalose in the gut.

Nanobodies that bacteria secrete only in the presence of a biomarker treat inflammatory bowel disease at the site of inflammation.

A new vaccination schedule pumps up the immune response to human immunodeficiency virus, overcoming a barrier that has frustrated vaccine designers.

Synchrony between the reward system and the auditory cortex in the brain underlies the positive effects of music on mood.

A new method for tracking CAR T cells in patients with blood cancers relies on a probe that binds directly to the therapeutic cells’ antigen receptor.

Drug repurposing trials for ichthyosis reveal complexity in the long-untreated disease.

Researchers studied an antidepressant that may help treat neuropathic pain.

The enzyme PGK1 sets the rate of cellular energy production and may be an ideal drug target when Parkinson’s disease neurons struggle to fuel themselves.

Bacteria’s constant interaction with viruses has led them to evolve antiviral strategies.

Michael Bollong and his team discovered a way to restore lung stem cells’ regenerative capacity and a potential drug for idiopathic pulmonary fibrosis.

The therapy met its primary endpoints in two Phase 3 studies and offers a new approach for the tens of millions of people living with the psychiatric condition.